| Jun 29, 2011
| 5:01 AM
Thomas McDonough of Towson, asks if U.S. taxpayer dollars sent to fight AIDS in Africa are not better used right here in Baltimore or Detroit, at least for now ("African AIDS money better spent at home," June 25). Senora McGuire of Dundalk deplores the...
| Jun 28, 2011
| 2:16 PM
In an effort to increase the immunization rates for school-age children, the Harford County Health Department will be holding early Back-to School Immunization Clinics for uninsured and underinsured students.
Each year, the Harford County Health...
| Jul 11, 2011
The topics of vaccines and vaccine safety spark emotional outbursts at scientific meetings and family dinner tables alike. But many of these debates are remarkably fact-free. Surprisingly few people — not just concerned parents but also doctors,...
| Sep 8, 2011
Hepatitis C has long been a problem with a low rate of cure. But new drug therapies are in use and others are on the horizon, according to Dr. Paul J. Thuluvath, chief of gastroenterology at Mercy Medical Center and the medical director of the Institute...
| Apr 9, 2009
Marvin Webster lived the good life at Morgan State University in the early 1970s. He was the "Human Eraser," a 7-foot-1 shot blocker who intimidated opponents on the basketball court and who charmed friends and teammates off it with his caring, selfless...
| Nov 4, 2007
While just a teenager in the 1970s, she danced on The Block, where she snorted cocaine and heroin and sold sex in backrooms. Later, with her addictions firmly rooted, she set out on her own, offering her body on the streets of West Baltimore as a deadly...
| Mar 29, 2009
The U.S. Army has quietly altered or abandoned some of its more experimental medical treatments for troops injured in combat, as advances it once hailed as groundbreaking are foundlargely ineffective or perhaps even dangerous.
Advanced battle dressings,...
| Dec 10, 2013
| 11:31 AM
(Reuters) - AbbVie Inc's all-oral hepatitis C therapy cured 96 percent of difficult-to-treat patients in a late-stage clinical trial after 12 weeks, keeping the company well placed in a highly competitive race to deliver new treatments for the serious...
| Dec 6, 2013
| 3:07 PM
On Friday, the Food and Drug Administration announced its approval of the new drug Sovaldi, sofosbuvir, for hepatitis C.
In clinical trials, the polymerase inhibitor, the first used in hepatitis C treatment, has shown a more than 90 percent success rate...
| Dec 6, 2013
| 4:15 PM
(Reuters) - U.S. regulators on Friday approved Gilead Sciences Inc's Sovaldi as a potentially easier cure for chronic infection with the liver-destroying hepatitis C virus.
The once-a-day pill is the first approved to treat certain types of hepatitis C...
| Dec 2, 2013
| 1:09 PM
CONCORD, New Hampshire (Reuters) - A former New Hampshire hospital technician who caused dozens of people to become infected with hepatitis after injecting himself with stolen pain killers was sentenced to 39 years in prison on Monday.
| Nov 22, 2013
| 3:51 PM
Nov 22 (Reuters) - U.S. regulators on Friday approved the
use of Johnson & Johnson's Olysio, also known as
simeprevir, as a treatment for chronic infection with the
liver-destroying hepatitis C virus.
Olysio, a protease inhibitor that blocks a specific...